In this video, Dr. Sigurdur Kristinsson of the University of Iceland describes the exciting new Black Swan Research Initiative® study, iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma). As part of the iStopMM study, 140,000 Icelanders over the age of 40 will have their blood samples tested for the precursor to multiple myeloma, or MGUS (monoclonal gammopathy of undetermined significance). If they test for MGUS, they are given the option to take part in a randomized clinical trial to treat or prevent the progression of MM. Dr. Kristinsson explains the four aims of this groundbreaking study in this video. 

Previous Post
Is MRD testing ready for “prime time”?
Next Post
IMF’s Black Swan Research Initiative®: ASCENT Trial

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.